ArticleSLAS discovery : advancing life sciences R & D2026
In silico prioritization and cheminformatics identify structurally diverse small-molecule inhibitors of Lassa virus glycoprotein-mediated membrane fusion.
Article in SLAS discovery : advancing life sciences R & D, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- In silico prioritization and cheminformatics identify structurally diverse small-molecule inhibitors of Lassa virus glycoprotein-mediated membrane fusion.SLAS discovery : advancing life sciences R & D · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
Lassa virus (LASV) is a hemorrhagic fever arenavirus of significant public health concern, infecting millions of people per year in Africa. Here, we developed a computational strategy to identify specific inhibitors of LASV glycoprotein-mediated virus cell entry, leveraging a previous screen of 297,156 small molecules from the MLPCN library, with the results deposited in the PubChem database. Data mining methods were developed to efficiently select small molecules prioritized for both potency and specificity in inhibiting Lassa virus infection. Cheminformatics classification then identified diverse chemical scaffolds that had not been previously reported. Representatives were evaluated against authentic LASV infection, yielding potencies as low as 10 nM. Investigation of the target mechanism compared vesicular stomatitis virus bearing the GPs of LASV, the distantly related Junín virus, and unrelated Ebola virus. The results identified three distinct chemical scaffolds that demonstrated strong LASV selectivity, each acting at the membrane fusion stage of virus cell entry. Sensitivity was mapped to regions of GP2 known to coordinate pH-triggered conformational rearrangements needed for membrane fusion. Time-of-addition experiments demonstrated loss of activity coincident with endosomal escape, and cell-cell fusion assays confirmed direct inhibition of GP-mediated syncytia formation. Together, these findings characterize each scaffold as an effective LASV fusion inhibitor and highlight the effectiveness of our combined computational and experimental approaches in identifying mechanistically informative antiviral scaffolds.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.